SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Gilead entered into an Eleventh Supplemental Indenture on May 20, 2026, governing the issuance of $3 billion in aggregate principal amount of senior notes across four series (2028, 2029, 2031, and 2034 notes) with interest rates ranging from 4.250% to 4.900%. The company intends to use net proceeds for general corporate purposes including potential acquisitions and strategic transactions.
View raw filing on EDGAR →Senseonics held its Annual Meeting of stockholders on May 20, 2026, at which six proposals were submitted to a vote: election of three directors (Goodnow, Kaufman, Larkin), advisory vote on named executive officer compensation, frequency of advisory compensation votes, ratification of KPMG LLP as auditor, approval of an amendment to increase authorized common shares from 70 million to 140 million, and approval of the 2026 Equity Incentive Plan. All proposals passed with disclosed vote tallies and broker non-votes.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from RLI Corp's May 14, 2026 annual meeting under Item 5.07. The filing reports voting outcomes on three proposals: (1) election of ten directors to one-year terms with detailed vote tallies for each nominee, (2) non-binding advisory approval of named executive officer compensation, and (3) ratification of Deloitte & Touche LLP as independent auditor. The tabular presentation of "For," "Against," "Abstentions," and "Broker Non-Votes" is the standard format for shareholder vote disclosures and is material to investors assessing board composition and governance.
View raw filing on EDGAR →NanoViricides entered into a Securities Purchase Agreement on May 15, 2026, for a registered direct offering of 1,133,334 shares of common stock at $1.50 per share, along with pre-funded warrants and common warrants, generating approximately $2.0 million in gross proceeds. The offering closed on May 18, 2026.
View raw filing on EDGAR →ProMIS Neurosciences held its Annual Meeting on May 20, 2026, with shareholders voting on three proposals: election of seven directors, ratification of Baker Tilly US, LLP as independent auditor, and approval of an amendment to the 2025 Stock Option and Incentive Plan increasing the share pool by 900,000 Common Shares. Detailed voting results were disclosed for each proposal.
View raw filing on EDGAR →The Company entered into an underwriting agreement for the issuance and sale of $500 million in 6.250% Notes due 2031. While this is a debt offering rather than a traditional M&A transaction, Item 1.01 covers "entry into a material definitive agreement," and a $500 million debt issuance is material to the registrant's capital structure and financing activities. The ma_activity classification best captures material financing transactions, though this could also be characterized as "other_material" if debt offerings are not considered within the scope of ma_activity.
View raw filing on EDGAR →The filing discloses quarterly financial results for the period ended March 31, 2026 through a press release and supplemental financial information attached as exhibits. This is a standard earnings release disclosure under Item 2.02, which is material to investors assessing the registrant's financial performance and condition.
View raw filing on EDGAR →The filing discloses Amendment No. 3 to the Executive Employment Agreement with CEO Brandon Torres Declet, modifying Section 2.6 to establish a new deal completion bonus structure contingent on an IPO, direct listing, or Change in Control. This is a compensatory arrangement modification for a named executive officer, fitting the exec_compensation category. The bonus structure (up to 1.5% of net proceeds or $225,000 minimum) is material to investor assessment of executive incentives and potential dilution in a liquidity event.
View raw filing on EDGAR →Skyworks entered into an Agreement and Plan of Merger with Qorvo on October 27, 2025, establishing a two-step merger structure whereby Skyworks' subsidiaries will merge with Qorvo, resulting in Qorvo becoming a wholly owned subsidiary of Skyworks. This is a material acquisition transaction requiring disclosure under Item 1.01 or related M&A provisions, and the filing explicitly states it is being made "in connection with certain transactions related to the Mergers."
View raw filing on EDGAR →Redwood Trust entered into an underwriting agreement on May 19, 2026 to sell $125 million in 9.75% senior notes due 2031, with a 30-day over-allotment option for an additional $18.75 million. This is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, but it does not fit neatly into the more specific event categories (it is not M&A, not a dilutive equity issuance, and not a covenant breach or going-concern disclosure). The disclosure is material as it represents a significant financing event.
View raw filing on EDGAR →The filing discloses entry into a Merger Agreement on May 17, 2026, whereby InnocsAI LLC will merge into a newly-formed subsidiary of Liminatus Pharma, with the Company acquiring a portfolio of oncology-focused biologic and cellular therapy programs (including CAR-T and antibody candidates). The consideration is 1.6 billion shares at $0.20 per share plus contingent value rights tied to future strategic exits. This is a material acquisition transaction requiring stockholder approval and SEC registration, clearly falling under Item 1.01 (Entry into Material Definitive Agreement) and the ma_activity event type.
View raw filing on EDGAR →The filing discloses the promotion of two executives—Tamara S. Johnson to Vice President, California Operations and Gregory D. Shimansky to Vice President, Rates and Regulatory Affairs—effective July 1, 2026. These are material appointments to senior officer positions at a regulated utility company where operational and regulatory leadership are critical to investor assessment.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Fifth District Bancorp's Annual Meeting of Stockholders held on May 18, 2026. The filing reports final voting tallies on director elections (Amie L. Lyons and David C. Nolan) and ratification of EisnerAmper LLP as independent auditor, which are standard matters submitted to stockholder votes at annual meetings. This is a material disclosure as it documents the outcome of corporate governance elections.
View raw filing on EDGAR →Charles Fitzgerald was appointed to the Board of Directors of Chiron Real Estate Inc., effective May 20, 2026. The appointment was disclosed in both Item 5.02 and Item 7.01 (Regulation FD Disclosure via press release), with details regarding his background, committee assignments, and independence determination.
View raw filing on EDGAR →The 2026 Annual Meeting of stockholders held on May 20, 2026 resulted in approval of four proposals: election of six directors, advisory vote on named executive officer compensation, amendment to the 2016 Equity Incentive Plan (extending term and increasing shares by 300,000), and ratification of Deloitte & Touche LLP as independent auditor. Complete voting tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are disclosed.
View raw filing on EDGAR →The disclosure announces the commencement of exchange offers and consent solicitations in connection with an anticipated merger transaction in which Qorvo will merge into a Skyworks subsidiary. This constitutes material M&A activity under Item 8.01, as the filing explicitly references "the anticipated transactions pursuant to which Qorvo, Inc. ("Qorvo") will merge with and into a subsidiary of Skyworks" and describes the related debt exchange and consent solicitation mechanics. The merger is a change of control event material to investors.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of MacroGenics' 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing presents voting outcomes for four proposals: election of four Class I directors (all elected), ratification of Ernst & Young LLP as independent auditor (approved), advisory approval of named executive officer compensation (approved), and amendment to the 2023 Equity Incentive Plan to increase available shares by 1,250,000 (approved). The detailed vote tallies for each proposal are the core content of this Item 5.07 disclosure.
View raw filing on EDGAR →The filing discloses two executive appointments: (1) Brian LaRose, the CFO, was appointed principal accounting officer on May 15, 2026, succeeding Leah Putnam; and (2) Tamara Ward was appointed as a director and Chair of the Compensation Committee on the same date. While both are appointments, the principal accounting officer role is a named executive officer position under Item 5.02, making this a material executive appointment. The appointment of a director with committee leadership responsibilities is also material to investors assessing governance and financial oversight.
View raw filing on EDGAR →The filing discloses issuance of $997.87 million in Asset Backed Notes on May 20, 2026, with supporting legal opinions from Sidley Austin LLP. While this represents a material financing event for the trust, it does not fit cleanly into the standard M&A or dilutive issuance categories—it is a securitization/ABS issuance by a special-purpose trust vehicle. The disclosure is routine for ABS trusts but material to investors in the notes themselves.
View raw filing on EDGAR →CareTrust REIT completed a registered public offering of 12.5 million shares of common stock at $40.225 per share on May 20, 2026, with an additional 1.875 million shares available under an underwriter option. The offering was conducted through a forward sale structure with Wells Fargo and JPMorgan Chase as forward purchasers. This is a material dilutive equity issuance that increases the company's share count and raises capital, disclosed pursuant to an effective S-3 shelf registration statement.
View raw filing on EDGAR →Trustco Bank Corp N.Y. held its 2026 Annual Meeting of Shareholders on May 19, 2026, with detailed voting results disclosed on four proposals: election of directors, approval of an amendment to the 2019 Equity Incentive Plan increasing available shares by 500,000, an advisory vote on executive compensation, and ratification of Crowe LLP as independent auditor.
View raw filing on EDGAR →The company's 2019 Equity Incentive Plan was amended to increase the number of shares available for issuance by 500,000 shares (from 700,000 to 1,200,000), a material compensatory arrangement affecting equity grants to officers and directors that was approved by shareholders at the 2026 Annual Meeting.
View raw filing on EDGAR →BD subsidiary issued €600 million in senior unsecured notes with full guarantee from the parent company to refinance existing debt and fund general corporate purposes.
View raw filing on EDGAR →Cenntro entered into securities purchase agreements for a private placement of 1,000,000 shares of common stock at $3.93 per share for approximately $3.93 million in gross proceeds. The issuance qualifies under Nasdaq Listing Rule 5635(d) as a 20% or greater dilution of outstanding common stock, exempt under Section 4(a)(2) and Regulation S with transfer restrictions and legend requirements.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from JetBlue's Annual Meeting of Stockholders held on May 14, 2026. The filing reports voting outcomes on four proposals: election of thirteen directors, advisory vote on executive compensation, ratification of Ernst & Young LLP as independent auditor, and approval of an amendment to the 2020 Crewmember Stock Purchase Plan. All results are presented with vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes), which is the standard format for shareholder vote result disclosures.
View raw filing on EDGAR →The filing discloses James Hardie's fiscal year 2026 Irish Statutory Accounts furnished under Item 7.01 (Regulation FD Disclosure). While this represents audited financial statements that would normally constitute an earnings release, the disclosure is explicitly furnished under Regulation FD rather than filed as a formal earnings announcement (Item 2.02), and the prose emphasizes non-filing status and liability disclaimers. This hybrid treatment—statutory accounts disclosed via FD rather than as a traditional earnings release—does not fit cleanly into the earnings_release category and is best classified as other_material given its materiality to investors assessing the registrant's financial position.
View raw filing on EDGAR →Item 2.02 disclosure of a press release issued on May 20, 2026 regarding Results of Operations and Financial Condition is a standard earnings release disclosure. The filing explicitly references a press release attached as Exhibit 99.1, which is the typical format for quarterly or annual financial results announcements.
View raw filing on EDGAR →Avista Corp. held its 2026 Annual Meeting of Shareholders on May 14, 2026, with voting results on four proposals: election of eleven directors (approved), ratification of Deloitte & Touche LLP as auditor (approved), advisory vote on executive compensation (approved), and an amendment to reduce shareholder approval thresholds from 80% to majority (not approved).
View raw filing on EDGAR →Avista Corp. entered into a material definitive agreement and created a direct financial obligation through the issuance of $160 million in first mortgage bonds ($90 million due 2029 at 4.77% and $70 million due 2056 at 6.10%), with an additional $70 million expected in August 2026, for refinancing and capital expenditure purposes.
View raw filing on EDGAR →The filing discloses elimination of an entire class of preferred stock (Series B Preferred Stock) via Certificate of Elimination following redemption of all outstanding shares on May 15, 2026. While this is a corporate governance/capital structure event rather than a specific taxonomy category, the redemption and elimination of a preferred stock class materially affects the registrant's capitalization and is disclosed under Item 5.03. This does not fit cleanly into earnings, executive changes, M&A, impairment, or other more specific event types, warranting classification as other_material.
View raw filing on EDGAR →The filing discloses CorVel Corporation's financial results for the three months and fiscal year ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly and annual financial performance information essential to assessing the registrant's financial condition and results of operations.
View raw filing on EDGAR →The filing discloses termination of a Cooperation Agreement between Entravision and the Stockholders (widow of former CEO Walter Ulloa and related trusts) that had governed board nomination rights and stockholder commitments since May 2023. While the termination itself is administrative, the agreement involved material governance arrangements and a significant shareholder relationship tied to the company's former leadership. The event does not fit neatly into the specific taxonomy categories (not an M&A activity, not a covenant breach, not a going-concern issue), making "other_material" the most appropriate classification for this governance-related termination.
View raw filing on EDGAR →The filing discloses a quarterly shareholder update for Q1 2026 under Item 7.01 (Regulation FD Disclosure), furnished but not filed. While this is a routine quarterly communication to shareholders, it does not fit the earnings_release category (which typically involves formal financial results as a press release exhibit) nor any other specific event type. The update would be material to shareholders assessing fund performance and status, warranting classification as other_material rather than a more specific category.
View raw filing on EDGAR →The filing discloses entry into a material definitive Underwriting Agreement for the issuance of $1.375 billion in Series 2026-A Senior Secured SAC Bonds by Appalachian Power Recovery Funding LLC, with Goldman Sachs, J.P. Morgan, and RBC Capital Markets as underwriters. While this is a debt issuance rather than a traditional M&A transaction, it represents a material financing activity that restructures the capital stack and involves multiple definitive agreements (Underwriting Agreement, Indenture, Intercreditor Agreement, Servicing Agreement, Purchase and Sale Agreement, and Administration Agreement). The magnitude ($1.375B) and complexity of the transaction structure make it material to investors' assessment of the registrant's financial position and capital strategy.
View raw filing on EDGAR →Akamai announced the pricing of $3 billion in aggregate principal amount of convertible senior notes ($1.5 billion due 2030 and $1.5 billion due 2032) in a private offering to qualified institutional buyers. This is a material dilutive issuance of convertible debt securities that will likely result in equity dilution upon conversion, consistent with Item 3.02 disclosure requirements and the dilutive_issuance event type.
View raw filing on EDGAR →The filing discloses an amendment to an Equity Purchase Agreement for the sale of the Company's Flyover flying theater attractions business to Flyover Attractions B.V., extending the outside termination date from May 21, 2026 to July 31, 2026. This constitutes material M&A activity—specifically a disposition of a business unit—that would materially affect a reasonable investor's assessment of the registrant's operations and financial position.
View raw filing on EDGAR →Robert D. Wright was appointed as President and Chief Executive Officer of Wendy's, effective May 21, 2026, and elected to the Board of Directors. The appointment includes compensatory arrangements with a base salary of $1 million, a performance-based bonus target of 175%, and LTIP awards totaling $5.5 million.
View raw filing on EDGAR →Lumen announced early results of cash tender offers for approximately $750 million in outstanding debt across multiple subsidiaries and note series. While debt repurchase activity can signal financial management or refinancing strategy, this disclosure does not fit cleanly into the more specific event categories (not M&A, not a covenant breach, not a restatement or going-concern issue). The tender offer itself—a material debt reduction initiative—is a significant corporate action affecting the capital structure and financial obligations of the registrant, warranting classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →The filing discloses entry into a second amended and restated LLC agreement for AGL EPCI I involving the admission of new members (AIMCo and additional Vintage Strategies vehicles) and a $54 million transfer of LLC interests. This constitutes a material change in the ownership and capital structure of an unconsolidated entity in which the Company holds interests, meeting the threshold for Item 1.01 material definitive agreement disclosure and representing a material transaction affecting the Company's investment portfolio.
View raw filing on EDGAR →American Water's finance subsidiary closed a $500 million senior notes offering on May 20, 2026, with net proceeds of approximately $498 million. While this is a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the dilutive_issuance category (which typically applies to equity securities or convertibles) nor any other more specific event type. The disclosure centers on debt issuance and refinancing activity rather than a discrete material event like M&A, impairment, or covenant breach.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Uwharrie Capital Corp's Annual Meeting of Shareholders held on May 19, 2026. The filing presents detailed vote tallies for four proposals: election of seven board directors, ratification of executive compensation resolution, frequency of advisory votes on compensation, and appointment of independent auditor. This is a textbook Item 5.07 disclosure and is material as it reflects shareholder approval of key governance matters including board composition and auditor appointment.
View raw filing on EDGAR →Eric Mellen, the Chief Financial Officer and Treasurer, provided notice of retirement effective June 10, 2026. The principal disclosed action is a named executive officer departing from his role. While the company notes it has begun a search for a replacement, the core event is the departure itself, making exec_departure the appropriate classification.
View raw filing on EDGAR →The disclosure centers on shareholder approval of the First Amendment to the 2020 Equity Incentive Plan, which increases the share pool by 3,000,000 shares and extends the plan term to 2036. This is a material compensatory arrangement amendment affecting equity grants available to officers and directors, disclosed under Item 5.02(e) and approved at the May 14, 2026 Annual Meeting of Shareholders.
View raw filing on EDGAR →AB Private Lending Fund completed an unregistered sale of 4,045 Class I common shares of beneficial interest to feeder vehicles under Section 4(a)(2) and Regulation S exemptions. This private placement raises capital while diluting existing shareholders' ownership interests.
View raw filing on EDGAR →The filing discloses the Company's Net Asset Value (NAV) per share as of April 30, 2026, across six classes of common shares and OP Units, calculated in accordance with board-approved valuation guidelines. While NAV reporting is a routine disclosure for REITs and non-traded funds, the detailed breakdown of NAV components and per-share values across multiple share classes would be material to investors evaluating the fund's performance and share pricing. This does not fit neatly into the more specific event categories (not earnings, not an executive change, not M&A, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →This disclosure reports the Company's Net Asset Value (NAV) per share as of April 30, 2026, broken down by share class, along with a detailed calculation of total NAV and its components. For a non-traded REIT like Fortress Credit Realty Income Trust, NAV per share is a critical valuation metric that directly informs investor pricing and redemption decisions. While this is a routine periodic disclosure for REITs, it is material to investors assessing the registrant's asset value and performance. The filing does not fit neatly into more specific event categories (not earnings, not M&A, not impairment, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from the 2026 Annual Meeting held on May 20, 2026, covering three proposals: election of seven directors, advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The filing directly matches Item 5.07 requirements and presents detailed vote tallies for each matter, making it material to investors' understanding of corporate governance and stakeholder approval.
View raw filing on EDGAR →Inovio Pharmaceuticals held its 2026 Annual Meeting of Stockholders on May 20, 2026, with shareholders voting on four proposals: election of eight directors, ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amended 2023 Omnibus Incentive Plan. All proposals passed with substantial majorities.
View raw filing on EDGAR →The filing discloses an unregistered sale of 211,900 Shares in a private placement to accredited investors under Rule 506(c) of Regulation D, representing an aggregate of 4,038.87 TAO worth $1,149,569. This is a classic dilutive issuance exempt from registration requirements, with Grayscale Securities acting as Authorized Participant and potential underwriter. The disclosure explicitly references Item 3.02 (Unregistered Sales of Equity Securities) and notes that periodic share creation may constitute ongoing distributions.
View raw filing on EDGAR →The Centers for Medicare & Medicaid Services expanded Medicare coverage for Personalis's NeXT Personal® test to include a new clinical indication (monitoring treatment response to neoadjuvant therapy in Stage II-III breast cancer patients). This regulatory approval expands the addressable market and revenue potential for a key product, which is material to investors. However, the event does not fit neatly into more specific categories (not an earnings release, M&A activity, impairment, or litigation), so it is classified as other_material.
View raw filing on EDGAR →